Document:

Exhibit
10.2

 

SEPARATION
AGREEMENT

 

This Separation
Agreement (this "Agreement") is made as of the 27th day of September, 2013,
between Enzon Pharmaceuticals, Inc., a Delaware corporation, with offices in Bridgewater, New Jersey (the "Company"),
and Andrew Rackear (the "Executive").

 

BACKGROUND

 

A.           This
Agreement constitutes the agreement between the Company and the Executive concerning the Executive's separation from employment
with the Company.

 

B.           This
Agreement supercedes and replaces the General Severance Agreement, dated September 22, 2010, between the Executive and the Company.

 

C.           The
Company desires to ensure that it can rely on the continued services of the Executive to assist with a transition in the business
of the Company, in order to avoid potentially material liabilities, obligations or losses that might arise from such transition
if the Company is not able to rely on employees who have experience with the operations of the Company.

 

D.           The
Executive desires to assure himself of financial support following the termination of his employment with the Company.

 

TERMS

 

In consideration
of the foregoing premises and for other good and valuable consideration, the Company and Executive agree as follows:

 

l.            Term
of Agreement. The term of this Agreement (the "Term") shall commence on the date hereof as first written above and
shall continue through the Separation Date. The term “Separation Date” means a date determined by the Chairman of
the Compensation Committee of the Company (the “Chairman”) in his absolute discretion occurring not earlier than October
1, 2013 and not later than December 31, 2013. The Company shall provide
the Executive with not less than two (2) weeks advance written notice of the occurrence of the Separation Date.

 

2.          Continuation
of Employment. During the Term, the Executive’s employment shall continue on substantially the same terms and conditions
as are in effect on the date hereof, subject to changes, if any, required by law. The Executive’s employment shall terminate
on the Separation Date.

 

3.          Payments
and Benefits Upon Termination.

 

(a) Subject
to the continued employment of the Executive through the Separation Date, the Company shall:

 

    	 

    	 

    

 

(i)
pay to the Executive in cash in a lump sum an amount equal to the sum of: (A) his base salary as in effect on the date hereof
(the “Base Salary”) through the Separation Date, to the extent theretore unpaid; (B) subject to affirmation by Chairman
that Executive has performed his transition responsibilities responsibly and in good faith, a pro-rated
portion (based on the portion of the year elapsed through the Separation Date) of his target bonus for 2013 of $122,000 (the “Target
Bonus”); and (C) $705,000 (such amount, “the Severance Payment”), representing one and one-half times the sum
of the Base Salary and Target Bonus. A portion of the Severance Payment in the amount of $100,000 shall be paid on the six month
anniversary of the Separation Date subject to the Condition. For purposes of this Agreement, the “Condition” means
that the Executive shall not have materially breached his obligations hereunder after reasonable notice and a reasonable opportunity
to cure. The remainder of the payment provided for by this paragraph 3(a)(i) shall be paid on the Separation Date;

 

(ii)
cause each outstanding and unvested equity-based compensation award granted to the Executive to continue to vest in accordance
with its terms subject to the Condition;

 

(iii)
commencing on the Separation Date, on an after-tax basis, pay the total premium cost for medical and dental coverage of the same
type as in effect on the date hereof under COBRA under the Company’s applicable health plan, if any, for a period of eighteen
(18) months, or if COBRA coverage is not available, promptly reimburse the Executive on an after-tax basis for the cost reasonably
incurred by him for comparable coverage obtained from another provider; provided, that the Company shall have no obligation under
this paragraph (iii) beginning as of the date Executive becomes eligible to obtain comparable benefits from a subsequent employer;
and

 

(iv)
on the Separation Date pay the Executive eight thousand dollars ($8,000.00) in respect of outplacement assistance.

 

(b) In the event
of the termination of the Executive’s employment by the Company without Cause prior to the Separation Date, the Executive
shall be entitled to all of the payments and benefits described in clauses (i) through (iv) of Section 3(a) above at the times
specified therein without regard to the Condition. For purposes of this Agreement, the term “Cause” shall mean:

 

(i)
the willful engaging by Executive in illegal conduct or gross misconduct which is demonstrably and materially injurious to the
Company; or

 

(ii)
Executive's willful refusal or inability to perform the duties of his position as an executive employed by the Company (other
than any such failure resulting from illness or incapacity), which refusal is demonstrably and materially injurious to the Company;
or

 

    	 

    	 

    

 

(iii)
Executive's material breach of his obligations under this Agreement or any employment agreement between the Company and Executive,
which breach is demonstrably and materially injurious to the Company;

 

(iv)
Executive's failure, where applicable, to maintain Executive's immigration status with the U.S. Immigration and Naturalization
Service or the Executive's failure to maintain valid employment authorization to provide services to the Company.

 

For purposes of this Agreement,
no act or failure to act on Executive's part shall be deemed "willful" unless done, or omitted to be done, by Executive
not in good faith and without reasonable belief that Executive's action of omission was in the best interest of the Company.

 

4.          General
Release. In consideration of the benefits Executive will receive under this Agreement, to which Executive would not otherwise
be entitled, Executive hereby releases and discharges Company, from any and all claims and/or causes of action, known and unknown,
which Executive may have or could claim to have against the Company up to and including the date of signing this Agreement. This
general release includes, but is not limited to, all claims arising from or during Executive’s employment or as a result
of the end of Executive’s employment and all claims arising under federal, state or local laws prohibiting employment discrimination
and/or harassment based upon age, race, sex, religion, handicap, national origin, sexual orientation, veteran status, or any other
protected characteristic, including but not limited to any and all claims arising under Title VII of the Civil Rights Act of 1964
and 1991, the Age Discrimination in Employment Act, the Employee Retirement Income Security Act of 1974, the Americans with Disabilities
Act, the Rehabilitation Act, the Equal Pay Act, the Family and Medical Leave Act, the Fair Labor Standard Act, the Sarbanes-Oxley
Act, the Health Insurance Portability and Accountability Act, the New Jersey Law Against Discrimination, the New Jersey Conscientious
Employee Protection Act, the New Jersey Family Leave Act, New Jersey Paid Leave Insurance Act, any applicable state wage and hour
laws, and/or any other state, federal, or municipal employment discrimination statutes (including but not limited to claims based
on age, sex, attainment of benefit plan rights, race, national origin, religion, handicap, sexual orientation, sexual harassment,
marital status, retaliation, and veteran status), and/or any other federal, state, or local statute, law, ordinance, or regulation
and/or pursuant to any other theory whatsoever, including but not limited to claims related to breach of implied or express employment
contracts, breach of the implied covenant of good faith and fair dealing, defamation, wrongful discharge, constructive discharge,
negligence of any kind, intentional infliction of emotional distress, whistleblowing, estoppel or detrimental reliance, public
policy, constitutional or tort claims, violation of the penal statutes and common law claims, or pursuant to any other theory
or claim whatsoever, arising out of or related to employment with the Company and/or any other occurrence from the beginning of
time to the date of this Agreement, whether presently asserted or otherwise. This Agreement specifically includes any and all
claims, demands, obligations, and/or causes of action for damages or penalties relating to or in any way connected with the matters
referred to herein, whether or not now known or suspected to exist, and whether or not specifically or particularly described
or referred to herein. Executive expressly waives any right or claim of right to assert hereafter that any claim, demand, obligation,
damage, liability and/or cause of action has, through ignorance, oversight or error, been omitted from the terms of this Agreement.
Executive represents that he has not heretofore assigned or transferred, or purported to assign or transfer, to any person or
entity, any claim, known or unknown to exist, or any portion thereof or interest therein, which such person has or may have had
against the Company. This Agreement and release does not, however, require Executive to waive the right to file a charge with
or participate before the Equal Employment Opportunity Commission, provided, however, that Executive gives up the right to recover
damages and attorneys' fees from such a proceeding. Nor does this Agreement and Release require Executive to waive vested rights,
if any, to pension, retiree, health or similar benefits under the Company's existing plans or Executive’s right to enforce
this Agreement. Unless otherwise prohibited by law, Executive agrees that should Executive file a lawsuit in court which is found
to be barred in whole or part by this Agreement, Executive will pay back to the Company any and all sums paid by the Company to
Executive or on Executive’s behalf pursuant to this Agreement and Executive will pay the legal fees incurred by the Company
in defending those claims found to be barred.

 

    	 

    	 

    

 

5.
Provision of Consulting Services. Executive agrees to render to the Company following the Separation Date such reasonable
consulting services as the Company may from time to time reasonably request. In consideration of such services, Company agrees
to pay to Executive a fee of $250 per hour for each hour or portion of an hour worked. The Company agrees to reimburse Executive
for his reasonable expenses incurred in connection with his performance of services hereunder, provided that any such expense
in excess of one thousand dollars ($1,000) must be pre-approved by the Company. Executive agrees to retain and provide the Company
with evidence of his performance of services and any such expenses reasonably acceptable to the Company as a condition to his
entitlement to any compensation hereunder.

 

6.          Indemnification
and Insurance. The Company shall indemnify Executive and hold him harmless from and against any claim, liability and expense
(including, without limitation, reasonable attorney fees) made against or incurred by him in connection with his employment by
the Company. Such indemnification shall be provided in a manner and to an extent that is not less favorable to the Executive as
the indemnification protection that is afforded by the Company to any other officer of comparable title and that is consistent
with industry custom and standards. The Company shall also reimburse the Executive for the reasonable cost of malpractice insurance
at a level appropriate in connection with the provision of the services contemplated hereunder.

 

    	 

    	 

    

 

7.          Section
409A.

 

(a) Anything
in this Agreement to the contrary notwithstanding, if at the time of Executive's separation from service within the meaning of
Section 409A of the Code, the Company determines that Executive is a "specified employee" within the meaning of Section
409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement
on account of the Executive's separation from service would be considered deferred compensation subject to the 20 percent additional
tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such
payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after the Executive's separation from service, or (B) Executive's death. It is the intention of the parties that none of the
payments provided herein be considered deferred compensation subject to such tax.

 

(b) To the extent
that any payment or benefit described in this Agreement constitutes "non-qualified deferred compensation" under Section
409A of the Code, and to the extent that such payment or benefit is payable upon Executive's termination of employment, then such
payments or benefits shall be payable only upon the Executive's "separation from service." The determination of whether
and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-1(h).

 

(c) The parties
intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner
so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may be amended, as
reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules
and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

 

(d) The Company
makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption
from, or the conditions of such Section.

 

8.          Miscellaneous.

 

(a) No Funding.
Nothing contained in this Agreement or otherwise shall require the Company to segregate, earmark or otherwise set aside any funds
or other assets to provide for any payments required to be made under this Agreement, and the rights of Executive to any benefits
hereunder shall be solely those of a general, unsecured creditor of the Company.

 

(b) Beneficiaries.
In the event of Executive's death, any amount or benefit payable or distributable to Executive pursuant to this Agreement shall
be paid to the beneficiary designated by Executive for such purpose in the last written instrument received by the Company prior
to Executive's death, if any, or, if no beneficiary has been designated, to Executive's estate, but such designation shall not
be deemed to supersede any beneficiary designation under any benefit plan of the Company.

 

    	 

    	 

    

 

(c) Entire
Agreement. This Agreement contains the entire understanding between the patiies hereto with respect to the subject matter
hereof and supersedes any prior understandings, agreements or representations, written or oral, relating to the subject matter
hereof.

 

(d) Counterparts.
This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together shall
constitute one and the same agreement, and any party hereto may execute this Agreement by signing any such counterpart.

 

(e) Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable
law but if any provision of this Agreement is held to be invalid, illegal or unenforceable under any applicable law or rule, the
validity, legality and enforceability of the other provision of this Agreement will not be affected or impaired thereby.

 

(f) Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the patiies hereto and their respective heirs,
personal representatives and, to the extent pem1itted by Section 7(g), successors and assigns. The Company will require its successors
to expressly assume its obligations under this Agreement.

 

(g) Assignability.
Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable
(including by operation of law) by either pmiy without the prior written consent of the other party to this Agreement.

 

(h) Modification,
Amendment, Waiver or Termination. No provision of this Agreement may be modified, amended, waived or terminated except by
an instrument in writing signed by the parties to this Agreement. No course of dealing between the parties will modify, amend,
waive or terminate any provision of this Agreement or any rights or obligations of any party under or by reason of this Agreement.
No delay on the part of the Company in exercising any right hereunder shall operate as a waiver of such right. No waiver, express
or implied, by the Company of any right or any breach by Executive shall constitute a waiver of any other right or breach by Executive.

 

(i) Notices.
All notices, consents, requests, instructions, approvals or other communications provided for herein shall be in writing and delivered
by personal delivery, overnight courier, mail, electronic facsimile or e-mail addressed to the receiving party at the address
set forth herein. All such communications shall be effective when received.

 

Address for
the Executive:

105 Lincoln
Rd.

Westfield, NJ
07090

 

Address for
the Company:

 

Enzon Pharmaceuticals,
Inc.

685 Route 202/206

Bridgewater,
New Jersey 08807

 

    	 

    	 

    

 

Attn:

 

Any party may
change the address set forth above by notice to each other party given as provided herein.

 

(j) Headings.
The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation
of this Agreement.

 

(k) Governing
Law. ALL MATTERS RELATING TO THE INTERPRETATION, CONSTRUCTION, VALIDITY AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED
BY THE INTERNAL LAWS OF THE STATE OF NEW JERSEY, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW PROVISIONS THEREOF.

 

(l) Arbitration.
Any claim or controversy arising out of or relating to this Agreement or the breach hereof shall be settled by arbitration in
accordance with the laws of the State of New Jersey. Such arbitration shall be conducted in the State of New Jersey in accordance
with the rules then existing of the American Arbitration Association. Judgment upon the award rendered by the arbitrators may
be entered in any court having jurisdiction thereof. In the event of any dispute arising under this Agreement, the respective
parties shall be responsible for the payment of their own legal fees and disbursements.

 

(m) Third-Party
Benefit. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations
or liabilities of any nature whatsoever.

 

(n) Withholding
Taxes. The Company may withhold from any benefits payable under this Agreement or any other agreement all federal, state,
city or other taxes as shall be required pursuant to any law or governmental regulation or ruling.

 

(o) No Right
to Continued Employment. Executive understands that this Agreement is not an employment contract and nothing contained herein
creates any right to continuous employment with the Company, or to employment by the Company for any specified period of time.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth above.

 

	 	ENZON PHARMACEUTICALS, INC.
	 	 
	 	/s/ Robert
    LeBuhn
	 	By: Robert LeBuhn
	 	Chairman, Compensation
    Committee
	 	 
	 	/s/ Andrew
    Rackear
	 	Andrew RackearAMENDMENT
NO. 1 TO

AGREEMENT
AND PLAN OF REORGANIZATION

 

This AMENDMENT NO. 1 to the AGREEMENT AND
PLAN OF REORGANIZATION is entered into as of November 6, 2013 by and among Andina Acquisition Corporation (“Andina”),
Andina Merger Sub, Inc. (“Merger Sub”), Tecnoglass S.A. (“Tecnoglass”) and C.I. Energia Solar S.A. E.S.
Windows (“ES” and together with Tecnoglass, the “Company”). Capitalized terms not otherwise defined herein
shall have the meaning given to such terms in the Merger Agreement (as defined below).

 

WHEREAS, the parties entered into that certain
Agreement and Plan of Reorganization dated as of August 17, 2013 (the “Merger Agreement”) providing for the Merger;
and

 

WHEREAS, in accordance with Section 10.10
of the Merger Agreement, the parties wish to amend certain terms and provisions of the Merger Agreement.

 

NOW, THEREFORE, in consideration of the foregoing
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.          The
references to February 28, 2014 in Sections 1.14(a) and (b), February 28, 2015 in Sections 1.14(c) and (d) and February 29, 2016
in Sections 1.14(e) and (f) of the Merger Agreement are hereby amended to be December 31, 2014, December 31, 2015 and December
31, 2016, respectively.

 

2.          The Merger
Agreement is hereby amended to add the following new Section 5.20:

 

“5.20     Fiscal
Year End. On or prior to the Closing, Parent shall change its fiscal year end to December 31.”

 

3.          The reference
to December 16, 2013 in Section 8.1(b) of the Merger Agreement is hereby amended to be December 22, 2013.

 

4.          Except as
specifically provided in this Amendment No. 1, no provision of the Merger Agreement is modified, changed, waived, discharged or
otherwise terminated and the Merger Agreement shall continue to be in full force and effect. This Amendment No. 1, together with
the Merger Agreement, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes
all other prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof.
This Amendment No. 1 may be executed and delivered (including by facsimile) in several counterparts, each of which shall constitute
an original and all of which, when taken together, shall constitute one agreement.

 

[Remainder of Page
Left Blank Intentionally]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, this Amendment No. 1 has been duly executed and delivered by the duly authorized officers of the parties as of
the date first written above.

 

	 	ANDINA ACQUISITION CORPORATION
	 	 	 
	 	By:  	/s/ B. Luke Weil
	 	 	Name: B. Luke Weil
	 	 	Title: Chief Executive Officer
	 	 	 
	 	ANDINA MERGER SUB, INC.
	 	 	 
	 	By:	/s/ B. Luke Weil
	 	 	Name: B. Luke Weil
	 	 	Title: Chief Executive Officer
	 	 	 
	 	TECNOGLASS S.A.
	 	 	 
	 	By:	/s/ Jose M. Daes
	 	 	Name: Jose M. Daes
	 	 	Title: Authorized Agent
	 	 	 
	 	C.I. ENERGIA SOLAR S.A. E.S. WINDOWS
	 	 	 
	 	By:	/s/ Jose M. Daes
	 	 	Name: Jose M. Daes
	 	 	Title: Authorized Agent

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]